Polyrizon Ltd. (PLRZ)

$1.55 -0.09 (-5.49%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 1,429,814
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza blockers. Polyrizon Ltd. was incorp...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 9 374 0120
Address:
5 Ha-Tidhar Street, Ra'anana, Israel
RoyalImperial
RoyalImperial Apr. 25 at 5:33 PM
MITQ ✅ Has that look for next week, one of the most undervalued and cleanest micro caps. Latest news + contracts rolling in Low float (6M) NO dilution Record earnings trend 📈. A $9M projector refresh contract plus other large projects shifting into FY2026 means a significant revenue surge is likely already locked in and coming. $ZEO $PLRZ $TZOO $XRTX watching ..
0 · Reply
patrick1956
patrick1956 Apr. 24 at 7:35 PM
$PLRZ ..this is a no lost situation....as this is an Israel company part of the Zionist regime...they now control the CDC...which means anything they submit will pass certification...load up...guaranteed $$$
0 · Reply
Rampageusa
Rampageusa Apr. 24 at 6:30 PM
$PLRZ watching…some day 19.5/24+=
0 · Reply
ReversedRunners
ReversedRunners Apr. 23 at 7:52 PM
$PLRZ df
0 · Reply
Rampageusa
Rampageusa Apr. 23 at 12:18 AM
$PLRZ this sleeping giant woke up today, now looking for a big moves like 20,30s and 50s range…
1 · Reply
uptrend2025
uptrend2025 Apr. 22 at 7:30 PM
$PLRZ 🤩
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 22 at 6:28 PM
$PLRZ RSI: 58.86, MACD: -0.2198 Vol: 1.02, MA20: 11.97, MA50: 12.95 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Rampageusa
Rampageusa Apr. 22 at 3:55 PM
$PLRZ 17.5/1.95i
0 · Reply
Tbirdyguy
Tbirdyguy Apr. 22 at 3:46 PM
$PLRZ let goooooo
0 · Reply
Stock_Catcher
Stock_Catcher Apr. 22 at 1:22 AM
Wealthy Wednesday Watchlist Pt. 9 $HIMS $GRPN $CORZ $VELO $PLRZ Let's Bank Tomorrow
0 · Reply
Latest News on PLRZ
Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements

Apr 8, 2026, 4:16 PM EDT - 16 days ago

Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements

Polyrizon Provides 2025 and Recent Highlights

Mar 26, 2026, 9:23 AM EDT - 4 weeks ago

Polyrizon Provides 2025 and Recent Highlights

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

Mar 25, 2026, 5:25 PM EDT - 4 weeks ago

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications

Mar 24, 2026, 8:47 AM EDT - 4 weeks ago

Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications

Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program

Mar 17, 2026, 8:25 AM EDT - 5 weeks ago

Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program

Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study

Mar 10, 2026, 7:55 AM EDT - 6 weeks ago

Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study

Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product

Feb 26, 2026, 8:12 AM EST - 2 months ago

Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product

Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker

Feb 17, 2026, 11:32 AM EST - 2 months ago

Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker

Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator

Feb 10, 2026, 6:55 AM EST - 2 months ago

Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator

Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation

Feb 6, 2026, 7:55 AM EST - 2 months ago

Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation

Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company

Feb 4, 2026, 7:12 AM EST - 2 months ago

Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company

Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker

Jan 22, 2026, 9:25 AM EST - 3 months ago

Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker

Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet

Jan 13, 2026, 8:39 AM EST - 3 months ago

Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet

Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™

Jan 8, 2026, 8:45 AM EST - 3 months ago

Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™

Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator

Jan 5, 2026, 9:07 AM EST - 3 months ago

Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator

As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated

Jan 2, 2026, 8:30 AM EST - 4 months ago

As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated

Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet

Dec 29, 2025, 7:20 AM EST - 4 months ago

Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet

Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses

Dec 19, 2025, 8:20 AM EST - 4 months ago

Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses

Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program

Dec 11, 2025, 8:15 AM EST - 4 months ago

Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program

Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray

Dec 8, 2025, 8:55 AM EST - 4 months ago

Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray

From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection

Dec 4, 2025, 7:32 AM EST - 5 months ago

From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection

Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product

Dec 3, 2025, 9:28 AM EST - 5 months ago

Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product

Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform

Dec 2, 2025, 7:55 AM EST - 5 months ago

Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform

Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation

Nov 6, 2025, 8:55 AM EST - 6 months ago

Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation

Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy

Oct 6, 2025, 8:21 AM EDT - 7 months ago

Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy

Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker

Sep 19, 2025, 8:15 AM EDT - 7 months ago

Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker

Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study

Sep 12, 2025, 7:26 AM EDT - 8 months ago

Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study

Polyrizon Regains Compliance with Nasdaq Listing Requirements

Aug 14, 2025, 8:14 AM EDT - 9 months ago

Polyrizon Regains Compliance with Nasdaq Listing Requirements

Polyrizon Retains Nasdaq Listing Following Hearings Panel

Jul 15, 2025, 7:55 AM EDT - 10 months ago

Polyrizon Retains Nasdaq Listing Following Hearings Panel

Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics

Jun 12, 2025, 7:32 AM EDT - 11 months ago

Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics

Polyrizon Announces Receipt of Nasdaq Delisting Notice

May 23, 2025, 4:15 PM EDT - 1 year ago

Polyrizon Announces Receipt of Nasdaq Delisting Notice

Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform

May 21, 2025, 7:10 AM EDT - 1 year ago

Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform

Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment

May 13, 2025, 7:45 AM EDT - 1 year ago

Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment

Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model

Apr 25, 2025, 7:37 AM EDT - 1 year ago

Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model

Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements

Apr 11, 2025, 4:15 PM EDT - 1 year ago

Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements

Polyrizon Engages Leading Branding Firm for Strategic Brand Development

Apr 2, 2025, 9:05 AM EDT - 1 year ago

Polyrizon Engages Leading Branding Firm for Strategic Brand Development

Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement

Apr 1, 2025, 4:09 PM EDT - 1 year ago

Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement

Polyrizon Ltd. Announces $17.0 Million Private Placement

Mar 31, 2025, 9:32 AM EDT - 1 year ago

Polyrizon Ltd. Announces $17.0 Million Private Placement

Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting

Mar 27, 2025, 8:25 AM EDT - 1 year ago

Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting

Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment

Mar 25, 2025, 4:04 PM EDT - 1 year ago

Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment

Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments

Mar 14, 2025, 8:35 AM EDT - 1 year ago

Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments

Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform

Mar 13, 2025, 7:51 AM EDT - 1 year ago

Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Mar 11, 2025, 4:27 PM EDT - 1 year ago

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform

Mar 10, 2025, 7:47 AM EDT - 1 year ago

Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform

Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform

Jan 30, 2025, 5:55 AM EST - 1 year ago

Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform

Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

Jan 23, 2025, 6:40 AM EST - 1 year ago

Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies

Dec 30, 2024, 6:25 AM EST - 1 year ago

Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies

Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs

Dec 19, 2024, 7:22 AM EST - 1 year ago

Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs

Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker

Dec 18, 2024, 6:25 AM EST - 1 year ago

Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker

Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance

Dec 13, 2024, 6:25 AM EST - 1 year ago

Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance

RoyalImperial
RoyalImperial Apr. 25 at 5:33 PM
MITQ ✅ Has that look for next week, one of the most undervalued and cleanest micro caps. Latest news + contracts rolling in Low float (6M) NO dilution Record earnings trend 📈. A $9M projector refresh contract plus other large projects shifting into FY2026 means a significant revenue surge is likely already locked in and coming. $ZEO $PLRZ $TZOO $XRTX watching ..
0 · Reply
patrick1956
patrick1956 Apr. 24 at 7:35 PM
$PLRZ ..this is a no lost situation....as this is an Israel company part of the Zionist regime...they now control the CDC...which means anything they submit will pass certification...load up...guaranteed $$$
0 · Reply
Rampageusa
Rampageusa Apr. 24 at 6:30 PM
$PLRZ watching…some day 19.5/24+=
0 · Reply
ReversedRunners
ReversedRunners Apr. 23 at 7:52 PM
$PLRZ df
0 · Reply
Rampageusa
Rampageusa Apr. 23 at 12:18 AM
$PLRZ this sleeping giant woke up today, now looking for a big moves like 20,30s and 50s range…
1 · Reply
uptrend2025
uptrend2025 Apr. 22 at 7:30 PM
$PLRZ 🤩
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 22 at 6:28 PM
$PLRZ RSI: 58.86, MACD: -0.2198 Vol: 1.02, MA20: 11.97, MA50: 12.95 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Rampageusa
Rampageusa Apr. 22 at 3:55 PM
$PLRZ 17.5/1.95i
0 · Reply
Tbirdyguy
Tbirdyguy Apr. 22 at 3:46 PM
$PLRZ let goooooo
0 · Reply
Stock_Catcher
Stock_Catcher Apr. 22 at 1:22 AM
Wealthy Wednesday Watchlist Pt. 9 $HIMS $GRPN $CORZ $VELO $PLRZ Let's Bank Tomorrow
0 · Reply
Tbirdyguy
Tbirdyguy Apr. 21 at 2:42 PM
$PLRZ volume, been a
0 · Reply
SpaceRunners
SpaceRunners Apr. 20 at 10:46 PM
$BLMZ $PLRZ $X $CLF PT
0 · Reply
Tbirdyguy
Tbirdyguy Apr. 20 at 4:22 PM
$PLRZ like watching paint dry.
0 · Reply
TrendyAce
TrendyAce Apr. 20 at 2:47 AM
$PLRZ Clinical Progress: The company recently signed an agreement with a global CRO to begin biocompatibility studies (ISO 10993) in Q2 2026. This is a critical step toward starting clinical trials for their nasal barrier technologies later this year.
1 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 15 at 4:11 PM
TechMediaBreaks – $PLRZ Closes $3.5 Million Registered Direct Offering and Concurrent Private Placement https://ibn.fm/L7sWI
1 · Reply
Tbirdyguy
Tbirdyguy Apr. 13 at 11:08 PM
$PLRZ I sold some, that means it's gonna pump now. You are welcome.
2 · Reply
LORDG00N
LORDG00N Apr. 10 at 3:54 PM
$PLRZ bruh
0 · Reply
focafoca99
focafoca99 Apr. 8 at 10:26 PM
$PLRZ closed its registered direct offering and concurrent private placement for gross proceeds of about $3.5 million.
1 · Reply
patrick1956
patrick1956 Apr. 8 at 6:44 PM
$PLRZ ...they fail their submission...
1 · Reply
Tbirdyguy
Tbirdyguy Apr. 8 at 4:11 PM
$PLRZ it's been way too much silence regarding pl16 which we last heard about in December when they requested classification from fda. I take it that did not go well?
0 · Reply
focafoca99
focafoca99 Apr. 7 at 9:55 PM
$PLRZ priced a $3.5 million registered direct offering alongside a private placement of warrants.
0 · Reply
patrick1956
patrick1956 Apr. 7 at 4:16 PM
$PLRZ ...keep those offerings coming...this 1 is 9$...per share with a warrant ...making the value with previous shares around $7.X....not including the warrants....could you say manipulation and dilution...lol
1 · Reply